Newsletter | October 24, 2023

10.24.23 -- FDA's Proposed Laboratory-Developed Tests Rule Raises Many Questions But Provides Few Answers

FEATURED EDITORIAL

FDA’s Proposed Laboratory-Developed Tests Rule Raises Many Questions But Provides Few Answers

The FDA has issued a new proposed rule on laboratory-developed tests (LDTs), expressly defining LDTs as a type of in vitro diagnostic (IVD) device, and subject to device regulations, including registration and listing, premarket review, and more. The FDA is accepting comments on the proposed rule through December 4.

Preformulation Of Excipients In Biologics Development

Most of the instability problems of a drug product come from excipients, in particular, they come from impurities in excipients. Those issues are best cleaned up in the preformulation period to determine excipient compatability.

MOST POPULAR NEWS

Roche IL-6 Is The First Immunoassay Approved To Aid Sepsis Diagnosis In Newborns

FloBio Receives FDA's Breakthrough Device Designation For Bleeding Risk Diag Test

Werfen Receives US FDA 510(K) Clearance For Aptiva

Scientists Dev Deep Learning-Based Biosensing Platform To Count Viral Particles Better

Avalon Globocare Partners With Qi Diagnostics To Co-Develop Dkair Breathalyzer Device

New York State Laboratory Approved For Genetic Testing Using Saliva

Roswell Park Licenses Rapid, Comprehensive Blood Test To Agilent

Thermo Fisher Scientific Signs Companion Diag Agreement With Boehringer Ingelheim

Oncotech AI-Powered Diag Mobile Cancer & Diabetes Screening Technology Ophtascan

Shimadzu Medical Systems USA Installs First Trinias SCORE Opera C12

SOPHiA GENETICS Collaborates With Memorial Sloan Kettering Cancer Center & Astrazeneca